LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 2 von insgesamt 2

Suchoptionen

  1. Artikel ; Online: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice.

    Nicole Caduff / Donal McHugh / Anita Murer / Patrick Rämer / Ana Raykova / Vanessa Landtwing / Lisa Rieble / Christian W Keller / Michael Prummer / Laurent Hoffmann / Janice K P Lam / Alan K S Chiang / Friedrich Raulf / Tarik Azzi / Christoph Berger / Tina Rubic-Schneider / Elisabetta Traggiai / Jan D Lünemann / Michael Kammüller /
    Christian Münz

    PLoS Pathogens, Vol 16, Iss 4, p e

    2020  Band 1008477

    Abstract: Post-transplant lymphoproliferative disorder (PTLD) is a potentially fatal complication after organ transplantation frequently associated with the Epstein-Barr virus (EBV). Immunosuppressive treatment is thought to allow the expansion of EBV-infected B ... ...

    Abstract Post-transplant lymphoproliferative disorder (PTLD) is a potentially fatal complication after organ transplantation frequently associated with the Epstein-Barr virus (EBV). Immunosuppressive treatment is thought to allow the expansion of EBV-infected B cells, which often express all eight oncogenic EBV latent proteins. Here, we assessed whether HLA-A2 transgenic humanized NSG mice treated with the immunosuppressant FK506 could be used to model EBV-PTLD. We found that FK506 treatment of EBV-infected mice led to an elevated viral burden, more frequent tumor formation and diminished EBV-induced T cell responses, indicative of reduced EBV-specific immune control. EBV latency III and lymphoproliferation-associated cellular transcripts were up-regulated in B cells from immunosuppressed animals, akin to the viral and host gene expression pattern found in EBV-PTLD. Utilizing an unbiased gene expression profiling approach, we identified genes differentially expressed in B cells of EBV-infected animals with and without FK506 treatment. Upon investigating the most promising candidates, we validated sCD30 as a marker of uncontrolled EBV proliferation in both humanized mice and in pediatric patients with EBV-PTLD. High levels of sCD30 have been previously associated with EBV-PTLD in patients. As such, we believe that humanized mice can indeed model aspects of EBV-PTLD development and may prove useful for the safety assessment of immunomodulatory therapies.
    Schlagwörter Immunologic diseases. Allergy ; RC581-607 ; Biology (General) ; QH301-705.5
    Thema/Rubrik (Code) 616 ; 570
    Sprache Englisch
    Erscheinungsdatum 2020-04-01T00:00:00Z
    Verlag Public Library of Science (PLoS)
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Correction

    Nicole Caduff / Donal McHugh / Anita Murer / Patrick Rämer / Ana Raykova / Vanessa Landtwing / Lisa Rieble / Christian W Keller / Michael Prummer / Laurent Hoffmann / Janice K P Lam / Alan K S Chiang / Friedrich Raulf / Tarik Azzi / Christoph Berger / Tina Rubic-Schneider / Elisabetta Traggiai / Jan D Lünemann / Michael Kammüller /
    Christian Münz

    PLoS Pathogens, Vol 16, Iss 12, p e

    Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice.

    2020  Band 1009167

    Abstract: This corrects the article DOI:10.1371/journal.ppat.1008477.]. ...

    Abstract [This corrects the article DOI:10.1371/journal.ppat.1008477.].
    Schlagwörter Immunologic diseases. Allergy ; RC581-607 ; Biology (General) ; QH301-705.5
    Sprache Englisch
    Erscheinungsdatum 2020-12-01T00:00:00Z
    Verlag Public Library of Science (PLoS)
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang